Dr. Samir Taneja, Consulting Editor, is stepping into the Guest Editor role for this issue of Urologic Clinics devoted to Prostate Cancer. He has assembled top experts to address the latest advances in the diagnosis and treatment of prostate cancer. Articles are devoted to the following topics: Whom to Biopsy: Pre-Diagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators; How to Biopsy: Transperineal vs. Tranrectal, Saturation vs. Targeted: What’s the Evidence; Pre-Diagnostic Risk and Assessment with Imaging and Image-guided Biopsy; Whom to treat: Post-Diagnostic Risk Assessment with Gleason score, Risk Models, and Genomic Classifier; Strategies for Staging and Utilization of Imaging; Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes; Focal Ablation of Early Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome; Extent of Lymphadenectomy at Time of Prostatectomy: An Evidence-based Approach; How to Radiate the Prostate: Hypofractionation, Sterotactic Body Radiation Therapy, and Conventional Intensity-Modulated Radiotherapy; Managing Relapse after Surgical Therapy: Adjuvant vs. Salvage Therapy; Newly diagnosed Metastatic Prostate Cancer – Has the Paradigm Changed; Role of Local therapy in Oligometastatic Prostate Cancer: Should we Expect Cure; Approaching the High-Risk Patient; and Castration-Resistant Prostate Cancer: An Algorithmic Approach. Readers will come away with state-of-the-art information on strategies for diagnosing, treating, and managing prostate cancer.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. CME Accreditation Page - p. iii 6. Contributors - p. v 7. Forthcoming Issues - p. xiii 8. Preface - p. xv 9. Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators - p. 517 10. How to Biopsy: Transperineal Versus Transrectal, Saturation Versus Targeted, What’s the Evidence? - p. 525 11. Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy - p. 535 12. Whom to Treat: Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier - p. 547 13. 68Gallium–Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer - p. 557 14. Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes - p. 565 15. Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome - p. 575 16. Extent of Lymphadenectomy at Time of Prostatectomy: An Evidence-Based Approach - p. 587 17. Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy - p. 597 18. Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed? - p. 611 19. The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure? - p. 623 20. Approach to the Patient with High-Risk Prostate Cancer - p. 635 21. Castration-Resistant Prostate Cancer: An Algorithmic Approach - p. 647
No hay muestra disponible
No hay ficha técnica disponible
Dr. Samir Taneja, Consulting Editor, is stepping into the Guest Editor role for this issue of Urologic Clinics devoted to Prostate Cancer. He has assembled top experts to address the latest advances in the diagnosis and treatment of prostate cancer. Articles are devoted to the following topics: Whom to Biopsy: Pre-Diagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators; How to Biopsy: Transperineal vs. Tranrectal, Saturation vs. Targeted: What’s the Evidence; Pre-Diagnostic Risk and Assessment with Imaging and Image-guided Biopsy; Whom to treat: Post-Diagnostic Risk Assessment with Gleason score, Risk Models, and Genomic Classifier; Strategies for Staging and Utilization of Imaging; Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes; Focal Ablation of Early Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome; Extent of Lymphadenectomy at Time of Prostatectomy: An Evidence-based Approach; How to Radiate the Prostate: Hypofractionation, Sterotactic Body Radiation Therapy, and Conventional Intensity-Modulated Radiotherapy; Managing Relapse after Surgical Therapy: Adjuvant vs. Salvage Therapy; Newly diagnosed Metastatic Prostate Cancer – Has the Paradigm Changed; Role of Local therapy in Oligometastatic Prostate Cancer: Should we Expect Cure; Approaching the High-Risk Patient; and Castration-Resistant Prostate Cancer: An Algorithmic Approach. Readers will come away with state-of-the-art information on strategies for diagnosing, treating, and managing prostate cancer.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. CME Accreditation Page - p. iii 6. Contributors - p. v 7. Forthcoming Issues - p. xiii 8. Preface - p. xv 9. Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators - p. 517 10. How to Biopsy: Transperineal Versus Transrectal, Saturation Versus Targeted, What’s the Evidence? - p. 525 11. Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy - p. 535 12. Whom to Treat: Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier - p. 547 13. 68Gallium–Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer - p. 557 14. Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes - p. 565 15. Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome - p. 575 16. Extent of Lymphadenectomy at Time of Prostatectomy: An Evidence-Based Approach - p. 587 17. Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy - p. 597 18. Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed? - p. 611 19. The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure? - p. 623 20. Approach to the Patient with High-Risk Prostate Cancer - p. 635 21. Castration-Resistant Prostate Cancer: An Algorithmic Approach - p. 647
No hay muestra disponible
No hay ficha técnica disponible
